Heart Failure

Videos

Heart Failure

The prevalence of heart failure (HF) continues to increase over time1 and affects >60 million people each year2.

Therefore, being aware of the latest data in the HF space and different treatment options is important in order to be able to apply findings to clinical practice when making treatment decisions for patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease, especially HF.

This section is supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company Alliance

Boehringer Ingelheim

Content on this section was partly provided by Boehringer Ingelheim. For any follow up questions please contact your local Boehringer Ingelheim representative.

Most Popular

Review articles

Pages

Systematic Analysis

Pages

Guidelines

Pages

Clinical Case Study

Pages

Press Announcements

Study Design

Pages

1.Heart disease and stroke statistics-2020 update: a report from the American Heart Association

Virani SS, Alonso A, Benjamin EJ, et al. Circulation 2020;141:e139-e596.

https://doi.org/10.1161/CIR.0000000000000757

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211-59.

https://doi.org/10.1016/S0140-6736(17)32154-2

Advances in Heart Failure: A Year of Discovery – SGLT2 Inhibitor Trials and Implications for Practice

PART 1: SGLT2 Inhibition in Changing the HF Paradigm

Learning objectives

  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM
  • Interpret the new data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM in relationship to the existing data.
  • Understand the implementation of the emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM for clinical practice.

 


Programme Outline
  • PART 1: SGLT2 Inhibition in Changing the HF ParadigmAndrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 2: Latest Evidence for SGLT2 in HF – 2020 So FarAndrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 3: Latest Evidence and Key Upcoming HFrEF Data 2020Andrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 4: The Future is Near – Unmet Needs in HFpEFCarolyn Lam
Supported by an unrestricted educational service from Boehringer Ingelheim

PART 2: Latest Evidence for SGLT2 in HF – 2020 So Far

Pages

Subscribe to RSS - Heart Failure